(Q79804177)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

[Evidence-based therapy of Raynaud's syndrome] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

M Distler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

J Distler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

D Kyburz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

U Müller-Ladner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

K Reich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

O Distler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

number of pages

5

1 reference

Zeitschrift fuer Rheumatologie

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

285-289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00393-006-0068-x

26 December 2019

exact match

0 references

cites work

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

1 reference

12 December 2020

Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon

1 reference

12 December 2020

Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules

1 reference

12 December 2020

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

1 reference

12 December 2020

Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis

1 reference

12 December 2020

The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon

1 reference

12 December 2020

An epidemiological survey of Raynaud's phenomenon

1 reference

12 December 2020

Local treatment with isosorbide dinitrate ointment in Raynaud's phenomenon

1 reference

12 December 2020

Iloprost therapy in systemic sclerosis

1 reference

12 December 2020

Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up

1 reference

12 December 2020

A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon

1 reference

12 December 2020

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

1 reference

12 December 2020

[Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature]

1 reference

12 December 2020

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

1 reference

12 December 2020

Amlodipine in the treatment of Raynaud's phenomenon

1 reference

12 December 2020

The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon

1 reference

12 December 2020

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

1 reference

12 December 2020

Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis

1 reference

12 December 2020

Clinical practice. Raynaud's Phenomenon

1 reference

12 December 2020

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

1 reference

12 December 2020

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease

1 reference

12 December 2020

Prazosin for Raynaud's phenomenon in progressive systemic sclerosis

1 reference

12 December 2020

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis

1 reference

12 December 2020

Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.

1 reference

12 December 2020

Subjective and objective assessment of enalapril in primary Raynaud's phenomenon

1 reference

12 December 2020

The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.

1 reference

12 December 2020

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

1 reference

12 December 2020

Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon

1 reference

12 December 2020

Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study

1 reference

12 December 2020

Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

1 reference

12 December 2020

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study

1 reference

12 December 2020

The clinical effect of felodipine and nifedipine in Raynaud's phenomenon

1 reference

12 December 2020

Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group

1 reference

12 December 2020

Treatment of scleroderma

1 reference

12 December 2020

A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases

1 reference

12 December 2020

Once daily felodipine in patients with primary Raynaud's phenomenon

1 reference

12 December 2020

Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.

1 reference

12 December 2020

Raynaud's phenomenon in mixed connective tissue disease

1 reference

12 December 2020

10.1007/S00393-006-0068-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804699%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference